Overview

Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

Status:
Terminated

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

This is a single arm, modified dose escalation, open label trial with the objectives of: (1) Determining a safe optimal dose of INCB007839 in combination with trastuzumab and docetaxel (2) Determining clinical efficacy and safety of INCB007839 in combination with trastuzumab and docetaxel.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Docetaxel
Trastuzumab